(VIANEWS) – The NASDAQ ended the session with argenx SE (ARGX) jumping 11.19% to $396.88 on Thursday while NASDAQ jumped 0.2% to $16,401.84.
argenx SE’s last close was $356.95, 35.19% under its 52-week high of $550.76.
About argenx SE
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Earnings Per Share
As for profitability, argenx SE has a trailing twelve months EPS of $-4.1.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.54%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 69.2% and positive 51.5% for the next.
Volatility
argenx SE’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.76%, a negative 0.57%, and a positive 1.52%.
argenx SE’s highest amplitude of average volatility was 1.76% (last week), 1.33% (last month), and 1.52% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth grew by 134.9%, now sitting on 1.27B for the twelve trailing months.
More news about argenx SE (ARGX).
